NYRADA INC. (ASX:NYR) 14 Rüdiger Weseloh Ph.D. Non-executive Director, joined the Board in June 2019 Rüdiger Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 20 years he has led more than 90 transactions for the healthcare division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, Rüdiger spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen. Rüdiger also served 5 years on the Supervisory Board of Cytotools AG, Freiburg, Germany. Interest in shares and options 1,483,332 shares and 1,800,000 unlisted options Special responsibilities N/A Directorship held in other listed entities (last 3 years) N/A Qualifications Rüdiger has a university diploma in Biochemistry from the University of Hannover and a PhD in Molecular Neurobiology, obtained at the Center for Molecular Neurobiology in Hamburg Ian Dixon Ph.D. Non-executive Director, joined the Board in September 2020 Dr Dixon brings to the Board extensive entrepreneurial and technical experience in founding, building and running listed and unlisted technology-based companies. In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics Ltd (ASX:CYP), a stem cell and regenerative medicine company. In 2014, Ian co-founded Cardio Therapeutics Pty Ltd and managed the PCSK9 cardiovascular discovery program until the company was acquired by Nyrada Inc in advance of the IPO of Nyrada in 2019. In 2018, the genetic medicines company founded by Ian listed on the ASX as Exopharm Ltd (ASX: EX1), now Entropy Neurodynamics Limited (ASX: ENP) Ian was also a co-inventor of several inventions in the exosome field, including a number of granted U.S. patents. Ian has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications. Interest in shares and options 9,780,699 shares and 1,800,000 unlisted options Special responsibilities Member of Audit & Risk Committee Member of Remuneration & Nomination Committee Directorship held in other listed entities (last 3 years) Entropy Neurodynamics Limited (ASX: ENP) previously, Exopharm Limited (ASX:EX1) – resigned on 1 May 2024. Qualifications PhD in biomedical engineering MBA Bachelor of Engineering
RkJQdWJsaXNoZXIy MjE2NDg3